Where The Buying Ran Strongest: 44 Small Cap Stocks At 52-Week Highs
Strength in small caps is concentrated, but the business stories behind the new highs vary widely.
Biotechnology leads the list with 8 names today. As of Thursday, August 6, 44 Small Cap stocks from the Russell 3000 are trading at their 52-week highs. The largest company on the list is Glaukos (GKOS), with a market value of about $9.9 billion. The central question is what kind of strength this is: are these prices earned by business performance, or are they simply a function of recent gains? The names below offer a first look.
The Biggest Names On The List
The table below shows the 10 largest of the 44 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| GKOS | $9.9 Bil | 0.0% | 1.5% | 11.8% | 94.2% |
| EAT | $9.8 Bil | 0.6% | 8.3% | 29.9% | 43.2% |
| PTGX | $9.5 Bil | 6.5% | 5.4% | 4.4% | 171.2% |
| VOYA | $9.4 Bil | 1.4% | 1.2% | 5.5% | 53.2% |
| APGE | $9.4 Bil | 0.2% | 0.1% | 0.9% | 250.9% |
| NEU | $8.3 Bil | 1.3% | 3.0% | 14.6% | 28.1% |
| LQDA | $7.9 Bil | 0.3% | 3.0% | 12.5% | 345.5% |
| VSXY | $7.6 Bil | 4.1% | 6.0% | 22.1% | 374.5% |
| CHE | $7.5 Bil | 0.5% | 2.7% | 14.5% | 29.0% |
| ACT | $6.9 Bil | 1.8% | 2.5% | 8.6% | 38.6% |
Is every new high built on the same foundation?
Consider the contrast between companies on the list. Brinker International (EAT) has gained 29.9% over the last month and trades at 21.2 times trailing earnings. Its revenue grew 11.8% over the last twelve months, and its operating margin is 10.7%.
Protagonist Therapeutics (PTGX) trades at a much higher 116.3 times trailing earnings. That valuation comes alongside revenue growth of 34.8% and an operating margin of 20.7%. Meanwhile, the list’s largest name, Glaukos (GKOS), shows revenue growth of 41.5% but a negative operating margin of -31.3%.
A 52-week high is a starting point for research, not a conclusion.
A stock at its strongest price of the last year is a sign of market recognition. Strength often persists. But a high is a price, not a verdict on the underlying business. The disciplined move is to use this list not as a signal to buy, but as a prompt to investigate. The essential question is always whether the business fundamentals can support the new valuation.
Before chasing any name on this list, ask what the company itself expects next. Our Guidance Momentum screen surfaces the stocks whose managements just raised their own outlooks, which is the momentum that tends to have staying power.
Strength Is A Clue. It Is Not A Plan
A stock at its 52-week high has momentum on its side, and momentum is a real force. It is also the most crowded signal in the market, and the difference between a run that lasts and one that tops is always the business underneath.
Checking that business, across thousands of names, is how the Trefis High Quality (HQ) Portfolio is assembled: roughly 30 companies that pass the quality screens, rebalanced on rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Let the highs point; let the discipline decide.